Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen.

Quotes for Scandion Oncology

Right Now

+/-
0.38
%
2,50%
Latest
15.56
High
15.98
Low
15.2
Volume
89 153
Turnover (SEK)
1 372 519
Value (MSEK)
296,5

Board

CEO

  • Nils Brünner

Chairman Of The Board

  • Peter Høngaard

Board

  • Carl Borrebäck
  • Christian Vinding Thomsen
  • Jørgen Bardenfleth
  • Thomas Feldthus

Videos

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2020-05-21 Delårsrapport 2020-Q1

  • 2020-05-27 Årsstämma 2019

  • 2020-08-20 Delårsrapport 2020-Q2

  • 2020-11-19 Delårsrapport 2020-Q3